Developer docs
API playgroundTry for free, no card

Search company profiles

Perfood

Full company profile

uuid0002jcu

Namestring
Perfood
Legal namestring
Perfood GmbH
Websiteurl
perfood.de
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Perfood GmbH is a Lübeck, Germany-based digital health company founded in 2017 that develops and commercializes a single product, glucura — a prescription-only digital therapeutic (DiGA) approved by the German Federal Institute for Drugs and Medical Devices (BfArM) for the management of Type 2 diabetes in non-insulin-dependent adults. The product is a smartphone application paired with a continuous glucose monitoring (CGM) sensor: the app ingests CGM data and dietary/activity inputs, uses an AI-based recommendation engine to evaluate meals against the user's individual glycemic response, and delivers personalized weekly nutrition and movement goals plus video coaching content. The company operates through a related entity, Perfood Laboratories GmbH, also based in Lübeck.

Perfood's commercial model is built on the German DiGA framework. Patients obtain a prescription from any licensed physician, submit it via Perfood's in-house prescription service (Antragsservice), and receive the product at 100% cost coverage from statutory health insurers (gesetzliche Krankenkassen), with most private insurers also covering it. A direct self-pay pathway exists but is secondary. Distribution is currently exclusively domestic through the prescription pathway, supported by a dedicated healthcare-professional (Fachkreise) channel with PVS prescription-system integration, content marketing, and a clinical-study publication effort. Headcount is reported in the 11–50 range.

The clinical evidence base is glucura's principal commercial asset: a multicenter, randomized controlled trial with 320 adults over six months demonstrated significant HbA1c reduction and weight loss with effects reportedly comparable to medication. Total disclosed funding is approximately $6 million across a 2020 Series A led by Boehringer Ingelheim Venture Fund (with UV-Cap and Verve Ventures) and a 2022 round with BONVENTURE. In 2025 the company publicly stated it is considering UK and US market expansion.

Short descriptiontext

Perfood GmbH is a Lübeck-based digital health company that develops glucura, a BfArM-approved prescription digital therapeutic (DiGA) for Type 2 diabetes management, combining continuous glucose monitoring sensors with AI-powered meal analysis and personalized lifestyle coaching, reimbursed by German statutory health insurers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLübeck, Germany
HQ citystring
Lübeck
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, diabetes management, continuous glucose monitoring, personalized nutrition coaching, digital health applications
Industry3 codes
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
Product category
Digital Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1DiGA Prescription Reimbursement (Statutory Health Insurance)
TypeSubscription Recurring
Description

As a listed DiGA (Digital Health Application) approved by BfArM, glucura is fully reimbursed by all statutory health insurance providers in Germany. Patients receive the product at 100% cost coverage with prescription. Follow-up prescriptions are also fully covered by health insurance.

glucura.de
2Private Health Insurance Reimbursement
TypeSubscription Recurring
Description

Many private health insurance providers in Germany also cover costs for glucura. Patients can inquire with their private insurer about reimbursement eligibility.

glucura.de
3Direct Self-Pay
TypeSubscription Recurring
Description

Patients can self-pay for glucura by contacting customer support and receiving an invoice for direct payment if insurance coverage is not available or preferred.

glucura.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Standard DiGA Prescription - Full Insurance Coverage
ModelSubscriptionBilling cadenceMulti-year contract
Notes

100% covered by statutory health insurance with valid prescription. No co-pay or additional costs for patients. Follow-up prescriptions also fully covered.

glucura.de
GTM typeB2C
B2C
Offering typeSoftware
Software
Brand1 record
1glucura
Description

A DiGA (Digital Health Application) approved by BfArM for Type 2 Diabetes management, using CGM-driven lifestyle coaching and personalized nutrition recommendations.

glucura.de
Core offering1 text field

Perfood develops glucura, a prescribed digital therapeutic (DiGA) for adults with non-insulin-dependent Type 2 diabetes. The app integrates continuous glucose monitoring (CGM) sensor data with AI-powered meal analysis and personalized lifestyle coaching to drive sustainable HbA1c reduction and weight loss. It is approved by BfArM and fully reimbursed by German statutory and many private health insurers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Significant HbA1c reduction over six months demonstrated in multicenter RCT with 320 adults
+4 more records
Product overview1 text field

Perfood offers a single unified product: glucura, a prescription-based digital therapeutic (DiGA) for type 2 diabetes management. The product combines a mobile app with a provided glucose sensor, leveraging AI to analyze meal responses and provide personalized recommendations. The system includes an nutrition diary, activity tracking, food scanner, recipes, and weekly behavioral goals—all delivered through a smartphone application that integrates continuous glucose monitoring data for real-time insights.

Product and service1 record
1glucura
CategoryDigital Therapeutics (DiGA)
Description

A clinically validated digital therapeutic (DiGA) for adults with non-insulin-dependent Type 2 diabetes that uses continuous glucose monitoring (CGM) sensors integrated with AI-powered meal analysis to provide personalized nutrition recommendations, real-time blood sugar tracking, and behavioral coaching for sustainable HbA1c reduction and weight management. Delivered via smartphone app paired with a glucose sensor, reimbursed 100% by German statutory health insurance on prescription.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Omada Health is a US digital chronic-disease management platform with diabetes and cardiometabolic programs reimbursed by employers and payers. It is comparable to glucura as a reimbursed digital therapeutic targeting Type 2 diabetes through behavioral coaching.

TypeEmerging player
Description

Welldoc develops AI-powered digital health products for diabetes, hypertension, and heart failure, with several FDA clearances. It overlaps with glucura on AI-driven chronic-disease coaching and offers a comparable regulatory and reimbursement playbook.

TypeDirect peer
Description

Virta Health is a US digital therapeutic that uses CGM-driven nutrition coaching to reverse Type 2 diabetes, with published clinical evidence showing HbA1c reduction. It is a direct functional peer to glucura's lifestyle-coaching model and a likely US-market competitor if Perfood expands there.

TypeDirect peer
Description

mySugr (acquired by Roche) is a Vienna-based diabetes self-management app with CGM integration and similar lifestyle coaching features. It is the most directly comparable competitor to glucura in the German-speaking market and competes for the same Type 2 diabetes patient and prescriber audience.

TypeBroad incumbent
Description

Dexcom is the leading CGM hardware manufacturer with its own patient-facing app and partner ecosystem. It is comparable as the dominant upstream provider of CGM data that glucura relies on, and could move downstream into coaching apps to compete directly with Perfood.

6Better Therapeutics
TypeEmerging player
Description

Better Therapeutics is a US prescription digital therapeutic company pursuing FDA-authorized software for Type 2 diabetes. It is comparable to glucura as a clinically validated, regulated digital therapeutic for Type 2 diabetes and a relevant precedent for US regulatory strategy.

TypeBroad incumbent
Description

Roche Diabetes Care (parent of mySugr, Accu-Chek) is a broad incumbent in diabetes hardware, software, and digital services. It is comparable to Perfood as the dominant integrated diabetes player whose mySugr subsidiary competes head-to-head with glucura for German patients and prescribers.

TypeDirect peer
Description

DarioHealth offers a connected diabetes management platform combining a smart glucometer, app, and AI-driven coaching. It overlaps with glucura on CGM/AI-driven personalization for Type 2 diabetes and shares a similar payer-reimbursement commercial model.

TypeDirect peer
Description

Glooko is a diabetes data management platform that aggregates CGM, insulin pump, and glucometer data with patient-facing apps. It is comparable to glucura as a CGM-integrated diabetes software platform serving patients and providers across multiple geographies.

10Abbott (FreeStyle Libre)
TypeBroad incumbent
Description

Abbott's FreeStyle Libre is the world's highest-volume consumer CGM system with an integrated patient app. It is comparable as a CGM incumbent that could bundle or partner on coaching functionality similar to glucura.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Perfood

Digital Therapeuticsperfood.de

Perfood GmbH is a Lübeck-based digital health company that develops glucura, a BfArM-approved prescription digital therapeutic (DiGA) for Type 2 diabetes management, combining continuous glucose monitoring sensors with AI-powered meal analysis and personalized lifestyle coaching, reimbursed by German statutory health insurers.

What Perfood does

Perfood GmbH is a Lübeck, Germany-based digital health company founded in 2017 that develops and commercializes a single product, glucura — a prescription-only digital therapeutic (DiGA) approved by the German Federal Institute for Drugs and Medical Devices (BfArM) for the management of Type 2 diabetes in non-insulin-dependent adults. The product is a smartphone application paired with a continuous glucose monitoring (CGM) sensor: the app ingests CGM data and dietary/activity inputs, uses an AI-based recommendation engine to evaluate meals against the user's individual glycemic response, and delivers personalized weekly nutrition and movement goals plus video coaching content. The company operates through a related entity, Perfood Laboratories GmbH, also based in Lübeck.

Perfood's commercial model is built on the German DiGA framework. Patients obtain a prescription from any licensed physician, submit it via Perfood's in-house prescription service (Antragsservice), and receive the product at 100% cost coverage from statutory health insurers (gesetzliche Krankenkassen), with most private insurers also covering it. A direct self-pay pathway exists but is secondary. Distribution is currently exclusively domestic through the prescription pathway, supported by a dedicated healthcare-professional (Fachkreise) channel with PVS prescription-system integration, content marketing, and a clinical-study publication effort. Headcount is reported in the 11–50 range.

The clinical evidence base is glucura's principal commercial asset: a multicenter, randomized controlled trial with 320 adults over six months demonstrated significant HbA1c reduction and weight loss with effects reportedly comparable to medication. Total disclosed funding is approximately $6 million across a 2020 Series A led by Boehringer Ingelheim Venture Fund (with UV-Cap and Verve Ventures) and a 2022 round with BONVENTURE. In 2025 the company publicly stated it is considering UK and US market expansion.

Perfood firmographics

Firmographics
Name
Perfood
Legal name
Perfood GmbH
Website
https://perfood.de
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Perfood GmbH is a Lübeck-based digital health company that develops glucura, a BfArM-approved prescription digital therapeutic (DiGA) for Type 2 diabetes management, combining continuous glucose monitoring sensors with AI-powered meal analysis and personalized lifestyle coaching, reimbursed by German statutory health insurers.
Ownership category
akta.pro rank

Perfood industry classification

Industry
Product category
Digital Therapeutics
akta.pro industry
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Digital therapeutics
  • Diabetes management
  • Continuous glucose monitoring
  • Personalized nutrition coaching
  • Digital health applications

Where Perfood is headquartered

Location

Headquarters

HQ city
Lübeck
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Perfood business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. DiGA Prescription Reimbursement (Statutory Health Insurance): As a listed DiGA (Digital Health Application) approved by BfArM, glucura is fully reimbursed by all statutory health insurance providers in Germany. Patients receive the product at 100% cost coverage with prescription. Follow-up prescriptions are also fully covered by health insurance.
  2. Private Health Insurance Reimbursement: Many private health insurance providers in Germany also cover costs for glucura. Patients can inquire with their private insurer about reimbursement eligibility.
  3. Direct Self-Pay: Patients can self-pay for glucura by contacting customer support and receiving an invoice for direct payment if insurance coverage is not available or preferred.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractStandard DiGA Prescription - Full Insurance Coverage

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Perfood product offering

Product offering

Core offering

Perfood develops glucura, a prescribed digital therapeutic (DiGA) for adults with non-insulin-dependent Type 2 diabetes. The app integrates continuous glucose monitoring (CGM) sensor data with AI-powered meal analysis and personalized lifestyle coaching to drive sustainable HbA1c reduction and weight loss. It is approved by BfArM and fully reimbursed by German statutory and many private health insurers.

Product overview

Perfood offers a single unified product: glucura, a prescription-based digital therapeutic (DiGA) for type 2 diabetes management. The product combines a mobile app with a provided glucose sensor, leveraging AI to analyze meal responses and provide personalized recommendations. The system includes an nutrition diary, activity tracking, food scanner, recipes, and weekly behavioral goals—all delivered through a smartphone application that integrates continuous glucose monitoring data for real-time insights.

Differentiator

Problem solved

Functional benefit

Brands

  • glucura: A DiGA (Digital Health Application) approved by BfArM for Type 2 Diabetes management, using CGM-driven lifestyle coaching and personalized nutrition recommendations.

Products and services

  • glucura A clinically validated digital therapeutic (DiGA) for adults with non-insulin-dependent Type 2 diabetes that uses continuous glucose monitoring (CGM) sensors integrated with AI-powered meal analysis to provide personalized nutrition recommendations, real-time blood sugar tracking, and behavioral coaching for sustainable HbA1c reduction and weight management. Delivered via smartphone app paired with a glucose sensor, reimbursed 100% by German statutory health insurance on prescription.

Quantifiable outcome

  • Significant HbA1c reduction over six months demonstrated in multicenter RCT with 320 adults
  • +4 more outcomes

Companies that use Perfood

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Perfood technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Perfood partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Perfood competitors and assessment

Company assessment

Direct peers

  • Omada Health: Omada Health is a US digital chronic-disease management platform with diabetes and cardiometabolic programs reimbursed by employers and payers. It is comparable to glucura as a reimbursed digital therapeutic targeting Type 2 diabetes through behavioral coaching.
  • Virta Health: Virta Health is a US digital therapeutic that uses CGM-driven nutrition coaching to reverse Type 2 diabetes, with published clinical evidence showing HbA1c reduction. It is a direct functional peer to glucura's lifestyle-coaching model and a likely US-market competitor if Perfood expands there.
  • mySugr: mySugr (acquired by Roche) is a Vienna-based diabetes self-management app with CGM integration and similar lifestyle coaching features. It is the most directly comparable competitor to glucura in the German-speaking market and competes for the same Type 2 diabetes patient and prescriber audience.
  • DarioHealth: DarioHealth offers a connected diabetes management platform combining a smart glucometer, app, and AI-driven coaching. It overlaps with glucura on CGM/AI-driven personalization for Type 2 diabetes and shares a similar payer-reimbursement commercial model.
  • Glooko: Glooko is a diabetes data management platform that aggregates CGM, insulin pump, and glucometer data with patient-facing apps. It is comparable to glucura as a CGM-integrated diabetes software platform serving patients and providers across multiple geographies.

Emerging players

  • Welldoc: Welldoc develops AI-powered digital health products for diabetes, hypertension, and heart failure, with several FDA clearances. It overlaps with glucura on AI-driven chronic-disease coaching and offers a comparable regulatory and reimbursement playbook.
  • Better Therapeutics: Better Therapeutics is a US prescription digital therapeutic company pursuing FDA-authorized software for Type 2 diabetes. It is comparable to glucura as a clinically validated, regulated digital therapeutic for Type 2 diabetes and a relevant precedent for US regulatory strategy.

Broad incumbents

  • Dexcom: Dexcom is the leading CGM hardware manufacturer with its own patient-facing app and partner ecosystem. It is comparable as the dominant upstream provider of CGM data that glucura relies on, and could move downstream into coaching apps to compete directly with Perfood.
  • Roche Diabetes Care: Roche Diabetes Care (parent of mySugr, Accu-Chek) is a broad incumbent in diabetes hardware, software, and digital services. It is comparable to Perfood as the dominant integrated diabetes player whose mySugr subsidiary competes head-to-head with glucura for German patients and prescribers.
  • Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the world's highest-volume consumer CGM system with an integrated patient app. It is comparable as a CGM incumbent that could bundle or partner on coaching functionality similar to glucura.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Perfood social profiles

Digital presence

Perfood compliance and trust

Trust signal

Compliance1 record

Perfood financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Perfood leadership team

Management profile

Number of profiles

Profiles5 records

Perfood funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Perfood M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perfood

What does Perfood do?

Perfood develops glucura, a prescribed digital therapeutic (DiGA) for adults with non-insulin-dependent Type 2 diabetes. The app integrates continuous glucose monitoring (CGM) sensor data with AI-powered meal analysis and personalized lifestyle coaching to drive sustainable HbA1c reduction and weight loss. It is approved by BfArM and fully reimbursed by German statutory and many private health insurers.

Is Perfood a public or private company?

Perfood is a private company. It is classified as venture growth investor backed and is currently operating.

When was Perfood founded?

Perfood was founded in 2017. It employs 11 to 50 people.

Where is Perfood based?

Perfood is headquartered in Lübeck, Germany, in the Europe region.

How does Perfood make money?

Three revenue lines are on record. DiGA Prescription Reimbursement (Statutory Health Insurance) is the primary driver. The others are private Health Insurance Reimbursement and direct Self-Pay.

Who are Perfood's main competitors?

Direct peers on record are Omada Health, Virta Health, mySugr, DarioHealth and Glooko. Emerging players are Welldoc and Better Therapeutics. Broad incumbents are Dexcom, Roche Diabetes Care and Abbott (FreeStyle Libre).

Does Perfood have an API?

No public API is recorded for Perfood.

What industry is Perfood in?

Perfood's product category is Digital Therapeutics. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals